BIN1 and cancer: As expected, the cisplatin sensitivity induced by si-RNF8 was significantly compromised by a pan-caspase inhibitor z-VAD-fmk (20 μM) or si-Caspase-3 in BIN1-deficient cancer cells (Figure 4C).